PDE5A and pulmonary arterial hypertension: The risk of PAH observed in patients who did not take PDE5-inhibitors were similar (OR 3.74; IC95%: 1.2–11.5; p<0.03) and less evident in patients who had never taken prostanoids (OR 2.65; IC95%:1.0–7.0; p<0,05).